Literature DB >> 6102490

Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue.

E G Spokes.   

Abstract

Dopamine, noradrenaline, glutamic acid decarboxylase and choline acetyltransferase were measured in various regions of brain obtained at autopsy from a large series of cases of Huntington's chorea, dying with advanced forms of the disease. Neurochemical values in the choreic cases were compared with those from control and schizophrenic cases. In brain tissue from choreic patients, highly significant increases in dopamine concentrations were found in the corpus striatum, nucleus accumbens and pars compacta of the substantia nigra. This is consistent with the hypothesis that the nigrostriatal dopamine system is spared and may exert a relatively unopposed action on striatal function. Noradrenaline concentrations were raised in the caudate nucleus, lateral pallidum and pars reticulata of the substantia nigra, indicating preservation of central noradrenergic pathways. Glutamic acid decarboxylase activity was reduced in all brain regions examined but, taking ante-mortem factors into account, the depletion was confined to the striatum and lateral pallidum. This is consistent with the view that striatal GABA-containing interneurons degenerate. Significant losses of choline acetyltransferase activity were observed in the striatum, nucleus accumbens, septal nuclei and hippocampus. The development of muscle rigidity in choreic patients did not significantly affect the neurochemical values. The neurochemical alterations in Huntington's chorea could not be attributed to differences in ante-mortem or post-mortem factors between the choreic group and the control and schizophrenic groups.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6102490     DOI: 10.1093/brain/103.1.179

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  51 in total

Review 1.  Imaging in cell-based therapy for neurodegenerative diseases.

Authors:  Deniz Kirik; Nathalie Breysse; Tomas Björklund; Laurent Besret; Philippe Hantraye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

Review 2.  Do neuroleptic drugs still have a place in neurological therapy?

Authors:  T Klockgether; J Dichgans
Journal:  J Neurol       Date:  1990-07       Impact factor: 4.849

Review 3.  Huntington's disease: the coming of age.

Authors:  Mritunjay Pandey; Usha Rajamma
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

4.  Striatal dopamine and homovanillic acid in Huntington's disease.

Authors:  G P Reynolds; N J Garrett
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

5.  Huntington's chorea-- measurements of somatostatin, substance P and cyclic nucleotides in the cerebrospinal fluid.

Authors:  H Cramer; J Kohler; G Oepen; G Schomburg; E Schröter
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

6.  Genetically determined predisposition to convulsions as the result of a generalized defect in the metabolism of catecholamines in the central nervous system.

Authors:  S A Dolina
Journal:  Neurosci Behav Physiol       Date:  1985 Nov-Dec

7.  The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy.

Authors:  D M Mann; R Oliver; J S Snowden
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

8.  Therapeutic Strategies in Huntington's Disease.

Authors:  Ichiro Kanazawa
Journal:  J Clin Neurol       Date:  2006-12-20       Impact factor: 3.077

Review 9.  The role of dopamine in Huntington's disease.

Authors:  Carlos Cepeda; Kerry P S Murphy; Martin Parent; Michael S Levine
Journal:  Prog Brain Res       Date:  2014       Impact factor: 2.453

Review 10.  The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start?

Authors:  Junghee Lee; Jung Hyun Boo; Hoon Ryu
Journal:  Adv Drug Deliv Rev       Date:  2009-08-27       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.